November 27, 2019

Predictors of Primary Response to Biologic Treatment Anti-TNF, Vedolizumab, and Ustekinumab in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice

Javier P. GisbertUniversitat de Miguel Hernández d'Elx MCMaría ChaparroInstituto de Salud Carlos III

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

In summary, currently no single marker fulfils all criteria for being an appropriate prognostic indicator of response to any biologic treatment in IBD.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Gisbert et al. (Wed,) studied this question.

synapsesocial.com/papers/69d8f8dcd2f7327e70ae4af8 https://doi.org/https://doi.org/10.1093/ecco-jcc/jjz195

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Systematic review: predicting and optimising response to anti‐<scp>TNF</scp> therapy in Crohn's disease – algorithm for practical management2015 · 312 citations
2Prediction of response to infliximab in Crohn's disease2005 · 13 citations
3Crohn’s disease genotypes of patients in remission<i>vs</i>relapses after infliximab discontinuation2012 · 27 citations
4Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review2018 · 70 citations
5Optimizing anti-TNF treatments in inflammatory bowel disease2013 · 423 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo